Last reviewed · How we verify
[11C] JNJ-42491293
Johnson & Johnson's [11C] JNJ-42491293 is a novel radiotracer in early development stages, with no FDA approval or clinical trials reported. It is designed for imaging applications, potentially offering new insights into disease mechanisms.
At a glance
| Generic name | [11C] JNJ-42491293 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: